Fubei Biotechnology (Suzhou)
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Fubei Biotechnology (Suzhou) - overview
Established
2017
Location
Suzhou, Jiangsu, China
Primary Industry
Biotechnology
About
Established in 2017 and based in Suzhou, China, Fubei Biotechnology (Suzhou) operates as a neurological drug developer dedicated to providing novel medicines for neurodegenerative diseases and neurological injuries. The co-founder and CEO, Xiaoming Guan, has 27 years of R&D and leadership experience in the pharmaceutical industry. Up to now, there are 9 innovative projects in the R&D pipeline, including small-molecule chemical drugs and large-molecule biologics. In addition, potential drug candidates FB1003 and FB1008 for the treatment of chronic pain and Alzheimer's disease are in the preclinical stage.
Current Investors
Gaorong Ventures, China Growth Capital, Foothill Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.4btechnologies.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Fubei Biotechnology (Suzhou) - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Unspecified Round | Completed | Fubei Biotechnology (Suzhou) | - | ||||||||
| Series A | Completed | Fubei Biotechnology (Suzhou) | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.